Edinger M - Search Results

1

Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence.

Negrin RS, Edinger M, Verneris M, Cao YA, Bachmann M, Contag ChH. Negrin RS, et al. Among authors: edinger m. Ann Hematol. 2002;81 Suppl 2:S44-5. Ann Hematol. 2002. PMID: 12611073 Review. No abstract available.

2

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Edinger M, et al. Blood. 2003 Jan 15;101(2):640-8. doi: 10.1182/blood-2002-06-1751. Epub 2002 Sep 26. Blood. 2003. PMID: 12393519 Free article.

3

Bioluminescence imaging of lymphocyte trafficking in vivo.

Hardy J, Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH. Hardy J, et al. Among authors: edinger m. Exp Hematol. 2001 Dec;29(12):1353-60. doi: 10.1016/s0301-472x(01)00756-1. Exp Hematol. 2001. PMID: 11750093 Free article.

4

Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.

Verneris MR, Baker J, Edinger M, Negrin RS. Verneris MR, et al. Among authors: edinger m. J Clin Immunol. 2002 May;22(3):131-6. doi: 10.1023/a:1015415928521. J Clin Immunol. 2002. PMID: 12078854 Review.

5

Understanding immune cell trafficking patterns via in vivo bioluminescence imaging.

Mandl S, Schimmelpfennig C, Edinger M, Negrin RS, Contag CH. Mandl S, et al. Among authors: edinger m. J Cell Biochem Suppl. 2002;39:239-48. doi: 10.1002/jcb.10454. J Cell Biochem Suppl. 2002. PMID: 12552623 Review.

6

Noninvasive assessment of tumor cell proliferation in animal models.

Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. Edinger M, et al. Neoplasia. 1999 Oct;1(4):303-10. doi: 10.1038/sj.neo.7900048. Neoplasia. 1999. PMID: 10935484 Free PMC article.

7

Advancing animal models of neoplasia through in vivo bioluminescence imaging.

Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, Contag CH. Edinger M, et al. Eur J Cancer. 2002 Nov;38(16):2128-36. doi: 10.1016/s0959-8049(02)00410-0. Eur J Cancer. 2002. PMID: 12387838 Review.

8

Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome.

Mandl SJ, Mari C, Edinger M, Negrin RS, Tait JF, Contag CH, Blankenberg FG. Mandl SJ, et al. Among authors: edinger m. Mol Imaging. 2004 Jan;3(1):1-8. doi: 10.1162/15353500200403157. Mol Imaging. 2004. PMID: 15142407

9

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.

Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. Leemhuis T, et al. Among authors: edinger m. Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7. doi: 10.1016/j.bbmt.2004.11.019. Biol Blood Marrow Transplant. 2005. PMID: 15744236 Free article. Clinical Trial.

10

Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.

Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karimi M, Cao YA, Marina N, Contag CH, Negrin RS. Verneris MR, et al. Among authors: edinger m. Clin Cancer Res. 2005 Jun 15;11(12):4561-70. doi: 10.1158/1078-0432.CCR-05-0157. Clin Cancer Res. 2005. PMID: 15958642

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters